Quote:

---

The Company previously requested rare pediatric disease designation (RPDD) from the FDA for ESS in the treatment of Giant Congenital Melanocytic Nevus (GCMN), which was not accepted; Cutanogen intends to appeal that decision. The Company believes ESS has the potential to receive RPDD for ESS in the treatment of pediatric severe burns.

---

https://finance.yahoo.com/news/amarantus-prov...00483.html

I was suprised we didn't get it for GCMN, i would really thought we would get it for such a rare disease!

We still have another shot at goal though!